Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine.

CONCLUSIONS: Treatment with desvenlafaxine 50 or 100 mg/d led to significantly greater categorical improvement in functional impairment versus placebo, and improvement in SDS subscale scores significantly predicted functional outcome. Monitoring patient progress early in the course of antidepressant treatment using a functional assessment such as the SDS may help clinicians determine whether or not treatment adjustments are needed. PMID: 29140227 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29140227?dopt=Abstract

Source: CNS Spectrums - November 15, 2017 Category: Neurology Authors: Soares CN, Zhang M, Boucher M Tags: CNS Spectr Source Type: research